Department of Pharmacology/Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Adham S. Abu-Taha
Department of Pharmacology/Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine
Preferred Abstract (Original):
The aim of the study was to investigate the extent
and time course of aminoglycoside (AG)-induced serum creatinine
elevation in patients with and without type 2 diabetes mellitus (DM2).
This prospective study included patients with and without DM2 who were
administered AG parenterally. The outcome of interest was the extent and
time course of serum creatinine elevation suggestive of renal injury
during AG therapy. Data were entered and analyzed using a statistical
package for social sciences (SPSS 16). Of 94 patients included in the
study, there were 42 DM2 and 52 non-DM2 patients. There was no
significant between-group difference in initial (P=0.18) and final serum
creatinine (P=0.15). Furthermore, no significant difference in serum
creatinine elevation was observed between patients with and without DM2
during the course of AG therapy. Eleven (26.2%) of 42 DM2 patients and
13 (25%) of 52 non-DM2 patients had an increase of ?44.2 μmol/L in serum
creatinine level during therapy (P=0.89). In DM2 group, a significant
rise (P=0.04) in serum creatinine level was evident on day 4 and maximum
rise (28%) from baseline value was evident on day 6 of therapy. Similar
extent and time course of serum creatinine elevation was observed in
non-DM2 group. In conclusion, type 2 diabetes mellitus is not a risk
factor for aminoglycoside-induced renal injury.